SVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Savara Inc (SVRA) is not a strong buy at the moment for a beginner, long-term investor. While there are positive insider buying trends and bullish technical indicators, the lack of significant financial growth, the FDA review delay for its key product, and no strong trading signals suggest holding off for now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive, indicating a potential upward trend. However, the RSI is neutral at 45.005, and the pivot level at 5.827 suggests the stock is trading near support and resistance levels, with no clear breakout signal.
Insider buying has increased significantly (373.33% over the last month), indicating confidence from company insiders. Additionally, the bullish moving averages support a potential upward trend.
The FDA has delayed the review of Savara's key product, molgramostim, by three months, which introduces uncertainty and could weigh on the stock's performance in the short term. The company's financials show no revenue growth and continued net losses.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved slightly but remains negative at -$32.24 million. EPS remains stagnant at -0.13. Overall, the financials indicate no significant growth or profitability.
No analyst rating or price target changes were provided, leaving no clear Wall Street sentiment to assess.
